Zacks Research Upgrades Corcept Therapeutics (NASDAQ:CORT) to “Strong-Buy”

Posted by George Bondi on Sep 30th, 2026

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday, Zacks reports.

A number of other equities research analysts also recently weighed in on CORT. HC Wainwright reiterated a “buy” rating and issued a $165.00 price target on shares of Corcept Therapeutics in a research report on Friday, September 18th. Piper Sandler reissued an “overweight” rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings raised Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $138.17.

Check Out Our Latest Stock Analysis on Corcept Therapeutics

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $114.74 on Monday. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $126.38. The firm has a market cap of $12.40 billion, a price-to-earnings ratio of 273.20 and a beta of 0.45. The firm’s 50-day simple moving average is $112.07 and its 200 day simple moving average is $79.49.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same quarter in the previous year, the firm posted $0.29 EPS. The business’s revenue for the quarter was up 31.7% compared to the same quarter last year. Sell-side analysts anticipate that Corcept Therapeutics will post 1.86 EPS for the current year.

Insider Buying and Selling

In other news, insider Roberto Vieira sold 58,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $110.76, for a total transaction of $6,460,963.08. Following the completion of the sale, the insider owned 4,242 shares of the company’s stock, valued at approximately $469,843.92. This represents a 93.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sean Maduck sold 30,955 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $125.58, for a total transaction of $3,887,328.90. Following the sale, the insider owned 9,755 shares in the company, valued at $1,225,032.90. This represents a 76.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 421,415 shares of company stock worth $48,465,845. 20.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently modified their holdings of the business. Envestnet Portfolio Solutions Inc. lifted its stake in Corcept Therapeutics by 1.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock valued at $923,000 after purchasing an additional 184 shares during the last quarter. State of Wyoming increased its holdings in shares of Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after buying an additional 186 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Corcept Therapeutics in the 2nd quarter valued at $27,000. Campbell Newman Asset Management Inc. boosted its holdings in shares of Corcept Therapeutics by 1.9% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 17,251 shares of the biotechnology company’s stock valued at $695,000 after acquiring an additional 320 shares in the last quarter. Finally, Gould Capital LLC grew its position in Corcept Therapeutics by 66.7% during the 1st quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing medicines that modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol activity in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s principal commercial product is Korlym (mifepristone), a glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery.